1. Home
  2. DCTH vs SAR Comparison

DCTH vs SAR Comparison

Compare DCTH & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • SAR
  • Stock Information
  • Founded
  • DCTH 1988
  • SAR 2007
  • Country
  • DCTH United States
  • SAR United States
  • Employees
  • DCTH 76
  • SAR N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • SAR Investment Managers
  • Sector
  • DCTH Health Care
  • SAR Finance
  • Exchange
  • DCTH Nasdaq
  • SAR Nasdaq
  • Market Cap
  • DCTH 426.3M
  • SAR 373.4M
  • IPO Year
  • DCTH N/A
  • SAR 2007
  • Fundamental
  • Price
  • DCTH $11.52
  • SAR $24.84
  • Analyst Decision
  • DCTH Strong Buy
  • SAR Hold
  • Analyst Count
  • DCTH 4
  • SAR 4
  • Target Price
  • DCTH $24.00
  • SAR $24.75
  • AVG Volume (30 Days)
  • DCTH 873.0K
  • SAR 101.9K
  • Earning Date
  • DCTH 08-04-2025
  • SAR 07-08-2025
  • Dividend Yield
  • DCTH N/A
  • SAR 12.14%
  • EPS Growth
  • DCTH N/A
  • SAR 105.87
  • EPS
  • DCTH N/A
  • SAR 2.47
  • Revenue
  • DCTH $53,850,000.00
  • SAR $142,495,705.00
  • Revenue This Year
  • DCTH $155.42
  • SAR N/A
  • Revenue Next Year
  • DCTH $37.93
  • SAR $1.25
  • P/E Ratio
  • DCTH N/A
  • SAR $10.06
  • Revenue Growth
  • DCTH 1068.87
  • SAR N/A
  • 52 Week Low
  • DCTH $7.17
  • SAR $21.10
  • 52 Week High
  • DCTH $18.23
  • SAR $26.49
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 32.83
  • SAR 52.87
  • Support Level
  • DCTH $12.11
  • SAR $24.01
  • Resistance Level
  • DCTH $14.15
  • SAR $25.47
  • Average True Range (ATR)
  • DCTH 0.57
  • SAR 0.37
  • MACD
  • DCTH -0.16
  • SAR -0.01
  • Stochastic Oscillator
  • DCTH 9.67
  • SAR 56.85

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

Share on Social Networks: